 Provider News VirginiaMarch 1, 2022 March 2022 Anthem Provider News - Virginia Contents State & Federal | Anthem Blue Cross and Blue Shield | Medicare Advantage | March 1, 2022 Pharmacy newsletterState & Federal | HealthKeepers, Inc. | Anthem HealthKeepers Plus Medicaid products | March 1, 2022 It is CAHPS survey time
Consumer surveys show that physicians are the most persuasive and influential source of information around vaccines. Anthem Blue Cross and Blue Shield (Anthem) and our affiliate HealthKeepers, Inc. are working to make it easier for physicians to offer their strong recommendations for vaccinations – especially vaccines for COVID-19 and influenza.
Anthem recently launched a single page to host resources for healthcare professionals related to vaccination, including a guide to talking with reluctant patients to respond to common concerns, and one comparing flu and COVID-19 vaccines.
We will continue to refresh and add to available content on the new vaccination resource page.
Visit our website for the most up-to-date COVID-19 information from Anthem.
Colorectal cancer is the most common cause of cancer death among Asian Americans,1 while African Americans are 40% more likely to die from the disease than any other racial or ethnic group2 in the United States. There are many possible reasons for the differences in survival rates among these racial and ethnic groups, but the common thread between them both is screening. For African Americans and Asian Americans, the reluctance could be cultural. They may not be as likely to ask about the screenings as their White counterparts.
Resources to help talk to patients about colorectal cancer screening
The Centers for Disease Control and Prevention website is an excellent resource for information about colorectal cancer that you can share with your patients. There is even a quiz to help your patients understand the importance of screening as a prevention.
We’ve also developed two videos for you to play in your patient waiting room, share with patients in the exam room, or share the link through your digital schedulers.
Colorectal screening for Asian Americans
Colorectal cancer screening for African Americans
Measure up: HEDIS® measures members ages 50–75 who receive the appropriate screening for colorectal cancer.
There are multiple test types that meet the requirement:
- Screening colonoscopy every 10 years
- Screening flexible sigmoidoscopy every 5 years
- Computed tomography (CT) colonography every 5 years
- Screening fecal occult blood test (FOBT) annually
- FIT DNA (i.e., Cologuard®) at home testing every 3 years
Coding Tips
For screening, use the appropriate code:
Screening
|
Commonly used billing codes
|
Flexible sigmoidoscopy
|
CPT: 45330–45335, 45337–45342, 45346, 45347, 45349, 45350
HCPC: G0104
|
FIT-DNA (i.e., Cologuard®)
|
CPT: 81528
|
Occult blood test (FOBT, FIT, guaiac)
|
CPT: 82270, 82274
HCPC: G0328
|
Colonoscopy
|
CPT: 44388–44394, 44401–44408, 45378–45386, 45398, 45388–45693
HCPC: G0105, G0121
|
CT Colonography
|
CPT: 74261, 74262
|
For exclusions, use the appropriate ICD-10 code:
ICD-10
|
Description
|
Z85.038
|
Personal history of other malignant neoplasm of large intestine
|
Z85.048
|
Personal history of other malignant neoplasm of rectum, rectosigmoid junction and anus
|
Z51.5
|
Encounter palliative care
|
Patients say they are more likely to have a cancer screening when their physician recommends it. What else can you do to influence cancer screenings?1
- Understand the power of the physician recommendation.
- Your recommendation is the most influential factor in whether a person decides to get screened.
- Patients are 90% more likely to get a screening when they reported a physician recommendation.
- “My doctor did not recommend it,” is the primary reason for screening avoidance.
- Recognize cultural barriers that may impact your diverse patients.
- Culturally sensitive conversations with your patients can help with fear, embarrassment, anxiety, and misconceptions about screenings.
- Go to mydiversepatients.com for information and resources.
- Measure the screening rates in your practice; it may not be as high as you think.
- Set goals to get screening rates up.
- Follow the HEDIS® guidelines included in this article to help accurately track your care gap closures.
- More screening doesn’t have to mean more work for you.
- Reach out to us about available member data – we may be able to help identify or supply access to data for those members who are due screenings.
- Develop a reminder system, which has been demonstrated to be effective, to remind you and staff that patients have screenings due.
- Help members access benefit information about screenings to eliminate the cost barrier.
- Log onto availity.com and use the Patient Information tab to run an eligibility and benefits inquiry.
- Members can access their benefit information by logging onto anthem.com, through Live Chat, or by downloading the Sydney Health App.
- Blue Cross Blue Shield Service Benefit Plan members, also known as Federal Employee Program® members, can access their benefit information by logging onto fepblue.org, or by downloading the fepblue App from the Apple Store or on Google Play.
Measure up: Cancer screening for women HEDIS® measure specifications
Organized and continuous screenings along with removal of precancerous lesions can lead to a 60% decrease in cervical cancer.2
Cervical Cancer Screening (CCS) is measured by the percentage of women 21 to 64 years of age who were screened for cervical cancer using either of the following criteria:
- Women 21–64 years of age who had cervical cytology performed within the last 3 years.
- Women 30–64 years of age who had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years.
- Women 30–64 years of age who had cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years.
Description
|
Code
|
Cervical cytology lab test
|
CPT: 88141–88143, 88147, 88148, 88150, 88152–88153, 88164–88167, 88174, 88175
HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091
LOINC: 10524-7, 18500-9, 19762-4, 19764-0, 19765-7, 19766-5, 19774-9, 33717-0, 47527-7, 47528-5
|
hrHPV lab test
|
CPT: 87620–87622, 87624–87625
HCPCS: G0476
LOINC: 21440-3, 30167-1, 38372-9, 59263-4, 59264-2, 59420-0, 69002-4, 71431-1, 75694-0, 77379-6, 77399-4, 77400-0, 82354-2, 82456-5, 82675-0
|
Absence of cervix diagnosis
|
ICD-10-CM: Q51.5, Z90.710, Z90.712
|
Hysterectomy with no residual cervix
|
CPT: 51925, 56308, 57530, 57531, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290, 58291, 58292, 58293, 58294, 58548, 58550, 58552, 58553, 58554, 58570, 58571, 58572, 58573, 58575, 58951, 58953, 58954, 58956, 59135
ICD-10-PCS: 0UTC0ZZ, 0UTC4ZZ, 0UTC7ZZ, 0UTC8ZZ
|
We are asking you to review your online provider directory information on a regular basis to ensure it is correct. Access your information by visiting anthem.com, select Providers. Next, under Provider Overview, choose Find Care.
Submit updates and corrections to your directory information using our online Provider Maintenance Form. Online update options include:
- Add/change an address location
- Name change
- Taxpayer identification number changes
- Provider leaving a group or a single location
- Phone/fax number changes
- Closing a practice location
Once you submit the form, we will send you an email acknowledging receipt of your request.
The Consolidated Appropriations Act (CAA) contains a provision that requires online provider directory information be reviewed and updated (if needed) at least every 90 days. By reviewing your information regularly, you can help us ensure your online provider directory information is current.
In the months ahead, you will notice that our correspondence to you has changed. We’ve simplified our requests for additional information by providing exactly the information you need to know, enabling quicker claims processing and faster payments.
Enabling digital responses
Our new correspondence format includes the easiest, fastest, and most efficient way to return the information requested. We’ll provide you with instructions about how to submit the information digitally. Whether it is through the Claims & Payments application for resubmission or by using the Attachments application, it is all in one place and accessible by logging onto Availity.com.
Digital responses to our request for additional information is one of the ways we can work together to reduce the amount of time and expense associated with claims processing.
Become an Availity user today
If you aren’t registered to use Availity, signing up is easy and 100% secure. There is no cost for our providers to register or to use any of the digital applications including our correspondence to you. Start by logging onto Availity.com and selecting the Register icon at the top of the home screen or use this link to access the registration page.
Beginning with dates of service on or after January 1, 2022, Anthem Blue Cross and Blue Shield and our affiliate HealthKeepers, Inc. will accept the new Place of Service code 10:
- Place of Service 02 (telehealth provided other than in patient’s home)
- Place of Service 10 (telehealth provided in patient’s home)
Services reported by a professional provider with a Place of Service 02 or 10 will be eligible for the office place of service reimbursement for our Commercial lines of business.
These correct coding updates align with the telehealth place of service updates released by the Centers for Medicare & Medicaid Services (CMS).
Claims filed with place of service 10 will pend for processing while we make claims system updates. All system updates are expected to be completed by March 11, 2022.
767-0322-PN-VA On January 10, 2022, updated Preventive Care Guidance (including guidance on screening colonoscopies beginning on page 11) was released by the Departments of Labor, Health and Human Services (HHS), and the Treasury. This new guidance applies to most of our Affordable Care Act-compliant, non-grandfathered health plans when services are provided in-network.
This new guidance indicates:
- On May 18, 2021, the USPSTF updated its recommendation for colorectal cancer screening. The USPSTF continues to recommend with an “A” rating screening for colorectal cancer in all adults aged 50 to 75 years and extended its recommendation with a “B” rating to adults aged 45 to 49 years. In its “Practice Considerations” section detailing screening strategies, the Final Recommendation Statement provides: “When stool-based tests reveal abnormal results, follow-up with colonoscopy is needed for further evaluation…. Positive results on stool-based screening tests require follow-up with colonoscopy for the screening benefits to be achieved.” Additionally, the Final Recommendation Statement provides with respect to direct visualization tests: “Abnormal findings identified by flexible sigmoidoscopy or CT colonography screening require follow-up colonoscopy for screening benefits to be achieved.”
For a follow-up colonoscopy after a positive non-invasive stool-based screening test or direct visualization screening test for colorectal cancer, in-network providers should code the claim as a screening colonoscopy rather than as a diagnostic colonoscopy.
Providers can contact the provider service number on the back of the member ID card to determine if a member’s plan includes this benefit.
Reveleer is the contracted vendor to gather member medical records on behalf of the Blue Cross and Blue Shield Federal Employee Program. We value the relationship with our providers and ask that you respond to the detailed requests in support of risk adjustment, HEDIS and other government required activities within the requested timeframe.
Reveleer will work with you to obtain records via fax, mail, remote electronic medical record (EMR) access, or onsite scanning/EMR download (as necessary). We ask that you comply promptly within five (5) business days of the record requests.
If you have any questions, you can reach a Reveleer representative by calling 855-454-6182 or contact Ify Ifezulike with Blue Cross Blue Shield Federal Employee Program at 419-494-6954.
The Anthem Blue Cross and Blue Shield Federal Employee Program (FEP) is making an address change for the clinical grievance and appeal submissions to help accommodate recent office environment and staffing changes.
The new address is effective immediately and should be used for all clinical grievance and appeal submissions, including new requests and medical records for existing requests.
New Address (effective immediately):
Anthem – FEP Appeals
P.O. Box 105318
Atlanta, GA 30348
Old Address:
Anthem – FEP Appeals
3075 Vandercar Way
Cincinnati OH 45209
The fax number for clinical appeals for the Anthem Federal Employee Program remains the same at 1-855-207-9935.
If you have any questions, please contact FEP customer service toll free at 800-552-6989.
CORRECTION: In the February 2022 edition of Provider News, we published updates for the drugs Tivdak, Byooviz and Skytrofa. Please be advised that the effective date for these updates has changed.
Updated effective date: June 1, 2022
Previous effective date: May 1, 2022
Below is the updated notice.
Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem Blue Cross and Blue Shield’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM), a separate company.
For Anthem Blue Cross and Blue Shield and our affiliate HealthKeepers, Inc., prior authorization clinical review of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of Oncology will still require pre-service clinical review by AIM Specialty Health®
This applies to members with Preferred Provider Organization (PPO), HealthKeepers (HMO), POS AdvantageOne, or Act Wise (CDH plans).
Please note, inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code.
The Health Plan requires that claims for injection services performed in the office setting must include the applicable HCPCS J-code, Q-code, or S-code, with the corresponding National Drug Code, for the injected substance. This requirement is consistent with CMS guidelines. A covered drug will not be eligible for reimbursement when the NDC is not reported on the same claim.
Prior authorization updates
Effective for dates of service on and after June 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.
Access our Clinical Criteria to view the complete information for these prior authorization updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
*ING-CC-0204
|
Tivdak
|
J3490, J3590, J9999
|
ING-CC-0072
|
Byooviz
|
J3490
|
ING-CC-0068
|
Skytrofa
|
J3490
|
* Oncology use is managed by AIM.
Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.
Step therapy updates
Effective for dates of service on and after June 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our existing specialty pharmacy medical step therapy review process.
Access our Clinical Criteria to view the complete information for these step therapy updates.
Clinical Criteria
|
Status
|
Drug
|
HCPCS or CPT Code(s)
|
ING-CC-0072
|
Non-Preferred
|
Byooviz
|
J3490
|
Quantity limit updates
Effective for dates of service on and after June 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.
Access our Clinical Criteria to view the complete information for these quantity limit updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
ING-CC-0072
|
Byooviz
|
J3490
|
Specialty pharmacy updates for Anthem Blue Cross and Blue Shield and our affiliate HealthKeepers, Inc. are listed below.
Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by Anthem’s medical specialty drug review team. Review of specialty pharmacy drugs for oncology use is managed by AIM Specialty Health® (AIM), a separate company.
For Anthem and HealthKeepers, Inc., prior authorization clinical review of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of Oncology will still require pre-service clinical review by AIM Specialty Health® . This applies to members with Preferred Provider Organization (PPO), HealthKeepers (HMO), POS AdvantageOne, and Act Wise (CDH plans).
Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications.
Inclusion of National Drug Code (NDC) code on your claim will help expedite claim processing of drugs billed with a Not Otherwise Classified (NOC) code. The Health Plan requires that claims for injection services performed in the office setting must include the applicable HCPCS J-code, Q-code, or S-code, with the corresponding National Drug Code, for the injected substance. This requirement is consistent with CMS guidelines. A covered drug will not be eligible for reimbursement when the NDC is not reported on the same claim.
Prior authorization updates
Effective for dates of service on and after June 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our prior authorization review process.
Access our Clinical Criteria to view the complete information for these prior authorization updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
ING-CC-0062
|
Hulio
Ixifi
|
J3590
Q5109
|
*ING-CC-0205
|
Fyarro
|
J3490
J3590
|
*ING-CC-0206
|
Besremi
|
J3490
J3590
|
ING-CC-0207
|
Vyvgart
|
C9399
J3490
J3590
|
ING-CC-0208
|
Adbry
|
J3490
|
ING-CC-0209
|
Leqvio
|
J3490
|
ING-CC-0004
|
Purified Cortrophin Gel
|
J3490
J3590
|
* Oncology use is managed by AIM.
Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.
Step therapy updates
Effective for dates of service on and after March 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be removed from our existing specialty pharmacy medical step therapy review process.
Access our Clinical Criteria to view the complete information for these step therapy updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
ING-CC-0072
|
Mvasi
Zirabev
|
Q5107
Q5118
|
Quantity limit updates
Effective for dates of service on and after June 1, 2022, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.
Access our Clinical Criteria to view the complete information for these quantity limit updates.
Clinical Criteria
|
Drug
|
HCPCS or CPT Code(s)
|
*ING-CC-0206
|
Besremi
|
J3490
J3590
|
ING-CC-0207
|
Vyvgart
|
C9399
J3490
J3590
|
ING-CC-0208
|
Adbry
|
J3490
|
ING-CC-0209
|
Leqvio
|
J3490
|
*Oncology use is managed by AIM.
Effective for dates of service on and after June 1, 2022, the following current clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.
For Anthem Blue Cross and Blue Shield and affiliate HealthKeepers, Inc., prior authorization of these specialty pharmacy drugs will be managed by Anthem. Drugs used for the treatment of Oncology will still require prior authorization by AIM Specialty Health® (AIM), a separate company. This applies to members with Preferred Provider Organization (PPO), Anthem HealthKeepers (HMO), POS AdvantageOne, and Act Wise (CDH plans).
Access the clinical criteria document information.
ING-CC-0062
|
Tumor Necrosis Factor Antagonists
|
ING-CC-0078
|
Orencia (abatacept)
|
ING-CC-0207
|
Vyvgart (efgartigimod alfa-fcab)
|
ING-CC-0208
|
Adbry (tralokinumab)
|
ING-CC-0209
|
Leqvio (inclisiran)
|
On June 1, 2022, prior authorization (PA) requirements will change for a code covered by Anthem Blue Cross and Blue Shield. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services (CMS) guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.
Prior authorization requirements will be added for the following codes:
- K1022 — Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type
Not all PA requirements are listed here. PA requirements are available to contracted providers on the provider website at Medicare Advantage Providers | Anthem.com > Login or by accessing Availity.*
Once logged in to Availity at http://availity.com, select Patient Registration > Authorizations & Referrals, then choose Authorizations or Auth/Referral Inquiry, as appropriate. Contracted and noncontracted providers who are unable to access Availity may call the number on the back of the member’s ID card.
Summary: On September 22, 2021, and November 19, 2021, the Pharmacy and Therapeutics (P&T) committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email.
See the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Share this notice with other members of your practice and office staff.
Please note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
Effective date
|
Document number
|
Clinical Criteria title
|
New or revised
|
March 9, 2022
|
*ING-CC-0204
|
Tivdak (tisotumab vedotin-tftv)
|
New
|
March 9, 2022
|
*ING-CC-0018
|
Lumizyme (alglucosidase alfa); Nexviazyme (avalglucosidase alfa-ngpf)
|
Revised
|
March 9, 2022
|
*ING-CC-0128
|
Tecentriq (atezolizumab)
|
Revised
|
March 9, 2022
|
*ING-CC-0012
|
Brineura (cerliponase alfa)
|
Revised
|
March 9, 2022
|
*ING-CC-0021
|
Fabrazyme (agalsidase beta)
|
Revised
|
March 9, 2022
|
*ING-CC-0017
|
Xiaflex (collagenase clostridium histolyticum)
|
Revised
|
March 9, 2022
|
*ING-CC-0026
|
Testosterone Injectable
|
Revised
|
March 9, 2022
|
*ING-CC-0100
|
Istodax (romidepsin)
|
Revised
|
March 9, 2022
|
*ING-CC-0125
|
Opdivo (nivolumab)
|
Revised
|
March 9, 2022
|
ING-CC-0197
|
Jemperli (dostarlimab-gxly)
|
Revised
|
March 9, 2022
|
ING-CC-0124
|
Keytruda (pembrolizumab)
|
Revised
|
March 9, 2022
|
*ING-CC-0061
|
GnRH Analogs for the Treatment of Non-Oncologic Indications
|
Revised
|
March 9, 2022
|
*ING-CC-0148
|
Agents for Hemophilia B
|
Revised
|
March 9, 2022
|
*ING-CC-0149
|
Select Clotting Agents for Bleeding Disorders
|
Revised
|
March 9, 2022
|
*ING-CC-0065
|
Agents for Hemophilia A and von Willebrand Disease
|
Revised
|
March 9, 2022
|
ING-CC-0168
|
Tecartus (brexucabtagene autoleucel)
|
Revised
|
March 9, 2022
|
*ING-CC-0195
|
Abecma (idecabtagene vicleucel)
|
Revised
|
March 9, 2022
|
*ING-CC-0001
|
Erythropoiesis Stimulating Agents
|
Revised
|
March 9, 2022
|
*ING-CC-0173
|
Enspryng (satralizumab-mwge)
|
Revised
|
March 9, 2022
|
*ING-CC-0170
|
Uplizna (inebilizumab-cdon)
|
Revised
|
March 9, 2022
|
*ING-CC-0041
|
Complement Inhibitors
|
Revised
|
March 9, 2022
|
*ING-CC-0071
|
Entyvio (vedolizumab)
|
Revised
|
March 9, 2022
|
*ING-CC-0064
|
Interleukin-1 Inhibitors
|
Revised
|
March 9, 2022
|
*ING-CC-0042
|
Monoclonal Antibodies to Interleukin-17
|
Revised
|
March 9, 2022
|
*ING-CC-0066
|
Monoclonal Antibodies to Interleukin-6
|
Revised
|
March 9, 2022
|
*ING-CC-0050
|
Monoclonal Antibodies to Interleukin-23
|
Revised
|
March 9, 2022
|
*ING-CC-0078
|
Orencia (abatacept)
|
Revised
|
March 9, 2022
|
*ING-CC-0063
|
Stelara (ustekinumab)
|
Revised
|
March 9, 2022
|
*ING-CC-0062
|
Tumor Necrosis Factor Antagonists
|
Revised
|
March 9, 2022
|
ING-CC-0003
|
Immunoglobulins
|
Revised
|
March 9, 2022
|
*ING-CC-0049
|
Radicava (edaravone)
|
Revised
|
March 9, 2022
|
*ING-CC-0075
|
Rituximab Agents for Non-Oncologic Indications
|
Revised
|
March 9, 2022
|
*ING-CC-0072
|
Selective Vascular Endothelial Growth Factor (VEGF) Antagonists
|
Revised
|
March 9, 2022
|
ING-CC-0107
|
Bevacizumab for Non-Ophthalmologic Indications
|
Revised
|
March 9, 2022
|
ING-CC-0106
|
Erbitux (cetuximab)
|
Revised
|
March 9, 2022
|
ING-CC-0105
|
Vectibix (panitumumab)
|
Revised
|
March 9, 2022
|
ING-CC-0043
|
Monoclonal Antibodies to Interleukin-5
|
Revised
|
March 9, 2022
|
*ING-CC-0068
|
Growth Hormone
|
Revised
|
Medication adherence improves overall member health and reduces hospitalizations. According to the World Health Organization, “Increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments.”1
Did you know?
- Most medication-related ER visits and hospitalizations in the U.S. (up to 70%) are caused by nonadherence to medication.2
- Studies show that 50 to 60% of patients are not taking their prescribed medications correctly or at all.3
- Improved adherence can drive positive health and economic outcomes.
- Patients’ adherence to statin medications at 12 months had improved LDL, reduced hospitalizations, and lower healthcare costs.4
Best practices for improving adherence
Support the implementation of medication nonadherence prevention strategies at each step of the medication use process:
- Prescribe maintenance medications for diabetes, cholesterol, and hypertension from the Anthem Blue Cross and Blue Shield (Anthem) Medicare Advantage $0 copay list.
- Encourage IngenioRx* Home Delivery to improve medication adherence, prevent refill gaps, avoid long waits at the pharmacy, and to reduce costs.
- IngenioRx Home Delivery members have 2 to 3% higher adherence rates
- E-prescribe, fax 800-378-0323, or phone-in prescriptions 833-203-1742
- Enrolled nonadherent patients may benefit from a multi-dose packaging of medications. CVS pharmacy® SimpleDose™ and PillPack are preferred pharmacies that offer multi-dose packaging with free home delivery. To enroll, go to:
- CVS.com/multidose or call 800-753-0596. Members may also enroll at their local CVS pharmacy. Members residing in the District of Columbia, Georgia, or South Carolina should call 844-650-1637.
- Pillpack.com/blue or call 866-282-9462.
- Offer members the opportunity to use ZipDrug, which offers free access to high performing pharmacies that provide customized medication services, hand-delivered prescriptions, and increase medication adherence rates. Go to anthem.com/zipdrug or call 844-947-3748.
- Patients who take medications for diabetes, cholesterol, and hypertension and enrolled in ZipDrug had a 4 to 10% increase in medication adherence rates.
- Encourage digital solutions: Sydney app can help Anthem members manage their medications through:
- Enrollment in ZipDrug
- Home delivery set-up
- Manage auto-refill and renew
- Text message reminders on prescriptions
Want more information regarding all the recommended best practices?
Best practices for medication adherence are reviewed in this brief video
Annual wellness visits (AWVs) are an important yet underutilized vehicle for ensuring successful value-based payment (VBP) arrangements. In 2022, there is an opportunity to increase your AWVs and, by extension, the health of your patients and your success in VBPs.
Per the American Academy of Family Practitioners (AAFP), “90 percent of patients who had received an AWV said they did so at the recommendation of their physician.” AWVs are a yearly exam (usually with a physician) to develop or update a personalized prevention plan and assess health status and any social, psychological, and behavioral health risks. An AWV can be a useful tool for improving quality of care, providing proactive care management, facilitating care coordination, and positively impacting up to 20 Medicare Advantage Star measure ratings for health plans.
There is often confusion between an AWV and an annual routine physical (ARP). The ARP is more comprehensive than an AWV. It consists of a physical exam by a physician and includes bloodwork, screenings, and other tests. The AWV involves checking standard measurements such as blood pressure, height, and weight. AWVs are free for Medicare Advantage members and, in many instances, can be conducted remotely via telehealth.
Note: CMS does allow both visit types to occur on the same date/time and providers can submit one claim encompassing each type.
There are many provider benefits for completing an AWV, including:
- Opportunity to develop a complete medical history for members
- Strengthened relationship with member
- Ability to provide proactive care to member
- Increased performance on quality metrics
- An ongoing, sustainable revenue stream for practice
- Vehicle for providers to obtain caregiver demographics
There are also many member benefits for completing an AWV, including:
- No copay
- Strengthened relationship with healthcare providers
- Annual comprehensive preventive evaluation
- Reduced risk of chronic conditions
- Keeps members out of the hospital
- Prevents accidents at home
In the ever-increasing emphasis on value-based care that focuses on shared savings, it is urgent for providers to complete an AWV for each of their assigned members. Doing so keeps members healthy, reduces healthcare costs, and can increase practice revenues.
Please note, this communication applies to Anthem HealthKeepers Plus, Medallion and Anthem HealthKeepers Plus, Commonwealth Coordinated Care Plus (Anthem CCC Plus) offered by HealthKeepers, Inc.
Consumer Assessment of Healthcare Providers and Systems (CAHPS®) is an annual standardized survey conducted between February and May to assess consumers’ experience with their providers and health plan. A random sample of your adult or child patients may receive the survey.
More than half of the questions used for scoring are directly impacted by providers. These questions are:
- When you needed care right way, how often did you get care as soon as you needed?
- How often did you get an appointment for a check-up or routine care as soon as you needed?
- How often was it easy to get the care, tests, or treatment you needed?
- How often did you get an appointment to see a specialist as soon as you needed?
- How often did your personal doctor seem informed and up to date about the care you got from other doctors or other health providers?
- How would you rate your personal doctor?
- How would you rate the specialist you see most often?
- How would you rate all your healthcare in the last six months?
Interested in how you can improve CAHPS performance?
HealthKeepers, Inc. offers an online course for providers and office staff designed to learn how to improve communication skills, build patient trust and commitment, and expand your knowledge of the CAHPS survey. The Improving the Patient Experience course is available at no cost and is eligible for one continuing medical education (CME) credit by the American Academy of Family Physicians. It can be accessed at:
https://www.mydiversepatients.com/le-ptexp.html.
If you have any questions about this communication, call Anthem HealthKeepers Plus, Medallion Provider Services at 800‑901‑0020 or Anthem CCC Plus Provider Services at 855‑323‑4687.
Please note, this communication applies to Anthem HealthKeepers Plus, Medallion and Anthem HealthKeepers Plus, Commonwealth Coordinated Care Plus (Anthem CCC Plus) offered by HealthKeepers, Inc.
To support the health of our members, HealthKeepers, Inc. is sending urinary tract infection (UTI) toolkits to select members who were seen in the ER for a UTI.
This useful kit contains:
- A water bottle to help your patient stay hydrated.
- UTI test strips with instructions on use if having symptoms. These are test strips that are also available over the counter.
- Basic instructions on how to use the toolkit and reasons to seek care.
If you have any questions about this communication, call Anthem HealthKeepers Plus, Medallion Provider Services at 800-901-0020 or Anthem CCC Plus Provider Services at 855-323-4687.
|